what is a glp-1 receptor agonist PDB-101: Molecule of the Month: Agonists New GLP-1 Guidelines for Type
Description
doi: 10.1007/s40257-024-00911-x
doi: 10.1111/obr.70079
(2025, June 10)
Shima Hadidchi, MD , takes a personalized approach to monitoring her patients progress on semaglutide GLP-1 or Zepbound for weight loss
The SELECT trial, as noted earlier, went a step further it tested Wegovy in overweight/obese individuals with cardiovascular disease (but without diabetes) and found a 20% reduction in heart attacks, stroke, or CV death ( [67] )
